Story perspectives

Regeneron and Tessera Partner for $150M AATD Treatment

12/2/2025

Summary

Story summary

Regeneron Pharmaceuticals and Tessera Therapeutics announced a collaboration to develop TSRA-196 for alpha-1 antitrypsin deficiency (AATD).
Regeneron will provide $150 million upfront and share future development costs and profits equally with Tessera.
TSRA-196 aims to correct the genetic mutation behind AATD, affecting about 200,000 people in the U.S. and Europe.
Tessera will lead initial human trials, while Regeneron will manage global development.

1 of 1

Story summary

Regeneron Pharmaceuticals and Tessera Therapeutics announced a collaboration to develop TSRA-196 for alpha-1 antitrypsin deficiency (AATD).
Regeneron will provide $150 million upfront and share future development costs and profits equally with Tessera.
TSRA-196 aims to correct the genetic mutation behind AATD, affecting about 200,000 people in the U.S. and Europe.
Tessera will lead initial human trials, while Regeneron will manage global development.